All In MedTech

FDA Clearance Tracker · P080011

BIOFINITY (COMFILCON A)

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Nov 19, 2008 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Nov 19, 2008

Approved

Time to decision

226 days

Received Apr 7, 2008. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P080011
Device name
BIOFINITY (COMFILCON A)
Applicant location
San Ramon, CA
Received
Apr 7, 2008
Decided
Nov 19, 2008
Decision
Approved
Supplements
201 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 886.5925
Specialty
Ophthalmology

Every decision under product code LPM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THEBIOFINITY (COMFILCON A) SOFT CONTACT LENS. THIS DEVICE IS INDICATED FOR USE AS FOLLOWS:BIOFINITY (COMFILCON A) SPHERE AND ASPHERC SOFT CONTACT LENSES ARE INDICATED FOR THECORRECTION OF AMETROPIA (MYOPIA AND HYPEROPIA) IN APHAKIC AND NON-APHAKIC PERSONS WITH NON-DISEASED EYES IN POWERS FROM -20.00 TO +20.00 DIOPTERS. THE LENSES MAY BE WORN BYPERSONS WHO EXHIBIT ASTIGMATISM OF 2.00 DIOPTERS OR LESS THAT DOES NOT INTERFERE WITHVISUAL ACUITY.BIOFINITY (COMFILCON A) TORIC SOFT CONTACT LENSES ARE INDICATED FOR THE CORRECTION OFAMETROPIA (MYOPIA OR HYPEROPIA WITH ASTIGMATISM) IN APHAKIC AND NON-APHAKIC PERSONSWITH NON-DISEASED EYES IN POWERS FROM -20.00 TO +20.00 DIOPTERS AND ASTIGMATICCORRECTIONS FROM -0.25 TO -5.00 DIOPTERS.BIOFINITY (COMFILCON A) MULTIFOCAL SOFT CONTACT LENSES ARE INDICATED FOR THE CORRECTION OF REFRACTIVE AMETROPIA (MYOPIA AND HYPEROPIA) AND EMMETROPIA WITH PRESBYOPIA INAPHAKIC AND NON-APHAKIC PERSONS WITH NON-DISEASED EYES IN POWERS FROM -20.00 TO +20.00 DIOPTERS WITH ADD POWERS FROM +0.50 TO +3.00 DIOPTERS. THE LENSES MAY BE WORN BY PERSONS WHO EXHIBIT ASTIGMATISM OF 2.00 DIOPTERS OR LESS THAT DOES NOT INTERFERE WITH VISUAL ACUITY.BIOFINITY (COMFILCON A) CONTACT LENSES MAY BE PRESCRIBED FOR EXTENDED WEAR FOR UP TO 6 NIGHTS AND 7 DAYS OF CONTINUOUS WEAR. IT IS RECOMMENDED THAT THE CONTACT LENS WEARER BE FIRST EVALUATED ON A DAILY WEAR SCHEDULE PRIOR TO OVERNIGHT WEAR. THE LENSES MAY BEPRESCRIBED FOR EITHER ONE WEEK DISPOSABLE WEAR OR FOR FREQUENT REPLACEMENT WITH CLEANING,DISINFECTION AND SCHEDULED REPLACEMENT. WHEN PRESCRIBED FOR FREQUENT REPLACEMENT, THELENSES MUST BE CLEANED AND DISINFECTED USING A CHEMICAL DISINFECTION SYSTEM ONLY.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LPM. The earliest in FDA's data is N16895, decided Mar 18, 1971.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for CooperVision, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.